INDIA; UNITED STATES OF AMERICA —Cohance Lifesciences is deploying $18 million in internal capital to restructure its targeted oncology operations in North America. The transactions involve increasing its equity ownership in New Jersey-based contract research and manufacturing outfit NJ Bio to 67.3% and acquiring a 65% controlling stake in preclinical drug developer Aruka Bio.
Cohance Lifesciences is an Indian contract development and manufacturing organization providing specialized active pharmaceutical ingredients and custom synthesis services for global life sciences companies. Aruka Bio focuses on early-stage antibody-drug conjugate therapies, while NJ Bio specializes in bioconjugation and payload-linker technologies.
This strategic move establishes a clear distinction between commercial contract manufacturing services and proprietary drug development. By separating service delivery from experimental therapy pipelines, the company aims to optimize operational management while offering end-to-end capabilities from early-stage development to full-scale commercial manufacturing.
The investment reflects accelerating demand within the global biotechnology and pharmaceutical sectors for antibody-drug conjugates, an advanced class of targeted cancer therapies. Biopharma companies are increasingly seeking integrated partners capable of navigating complex payload-linker chemistry and scaled manufacturing within tight regulatory environments.
For global investors and pharmaceutical clients, the consolidation streamlines supply chain dependency by unifying early synthesis with commercial scale-up. The inclusion of a proprietary drug discovery pipeline offers long-term licensing, co-development, and partnership potential across international oncology markets.
